These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33208570)

  • 41. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
    Oliva RV; Bakris GL
    J Am Soc Hypertens; 2014 May; 8(5):330-9. PubMed ID: 24631482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
    Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
    Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Medications for the Treatment of Diabetes.
    Garg SK; Giordano D
    Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
    [No Abstract]   [Full Text] [Related]  

  • 49. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
    Famulla S; Pieber TR; Eilbracht J; Neubacher D; Soleymanlou N; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Technol Ther; 2017 Jan; 19(1):49-60. PubMed ID: 27929674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial.
    Ajjan RA; Heller SR; Everett CC; Vargas-Palacios A; Higham R; Sharples L; Gorog DA; Rogers A; Reynolds C; Fernandez C; Rodrigues P; Sathyapalan T; Storey RF; Stocken DD
    Diabetes Care; 2023 Feb; 46(2):441-449. PubMed ID: 36516054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Novel CGM Metric-Gradient and Combining Mean Sensor Glucose Enable to Improve the Prediction of Nocturnal Hypoglycemic Events in Patients with Diabetes.
    Li J; Ma X; Tobore I; Liu Y; Kandwal A; Wang L; Lu J; Lu W; Bao Y; Zhou J; Nie Z
    J Diabetes Res; 2020; 2020():8830774. PubMed ID: 33204733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dapagliflozin for the treatment of type 1 diabetes mellitus.
    Pafili K; Maltezos E; Papanas N
    Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
    Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
    Tan X; Hu J
    Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease.
    Gerards MC; Venema GE; Patberg KW; Kross M; Potter van Loon BJ; Hageman IMG; Snijders D; Brandjes DPM; Hoekstra JBL; Vriesendorp TM; Gerdes VEA
    Diabetes Obes Metab; 2018 May; 20(5):1306-1310. PubMed ID: 29316157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.
    El Hage L; Kashyap SR; Rao P
    J Prim Care Community Health; 2019; 10():2150132719895188. PubMed ID: 31894715
    [No Abstract]   [Full Text] [Related]  

  • 58. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
    Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
    Moradi-Marjaneh R; Paseban M; Sahebkar A
    Phytother Res; 2019 Oct; 33(10):2518-2530. PubMed ID: 31359514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.